HB 2965 would add a new section to Arizona law governing the state board of pharmacy to prohibit manufacturers, repackagers, and their agents or affiliates from interfering with the distribution of 340B drugs to eligible covered entities. In practical terms, the bill bars those entities from denying, restricting, discriminating against, or otherwise limiting acquisition or delivery of 340B drugs to a covered entity, a contract pharmacy, or another authorized delivery location, unless federal law or HHS rules prohibit the receipt.
The bill also prohibits manufacturers and repackagers from conditioning access to 340B drugs on the submission of claims data or utilization data unless such sharing is required by the U.S. Department of Health and Human Services. It authorizes the Arizona State Board of Pharmacy to investigate complaints involving licensed or permitted persons or entities and to impose discipline, suspension, or revocation, and it allows the attorney general to enforce violations as unlawful practices under Arizona consumer protection law. The bill expressly states that it does not create a private right of action and includes severability language.
Impact
HB 2965 would create a new state enforcement framework for 340B drug distribution, adding protections for 340B covered entities and their contract pharmacies against manufacturer or repackager restrictions. It would also expand the Arizona State Board of Pharmacy’s oversight authority and give the attorney general a role in enforcing violations as unlawful practices under A.R.S. § 44-1522. The bill defines key terms by reference to federal law and Arizona’s existing 340B statute, and it includes a savings clause to avoid conflict with federal law and certain limited-distribution requirements.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or vote sentiment in the available materials. Based on the bill text alone, the measure appears to be a pro-340B access bill aimed at protecting covered entities from supply and data-sharing restrictions imposed by drug manufacturers or repackagers. The absence of recorded action in the provided history suggests the bill had not advanced far at the time of the snapshot.
Contention
The likely points of contention are the bill’s restrictions on manufacturer and repackager practices, especially the prohibition on conditioning 340B drug access on claims or utilization data. Opponents could view the bill as limiting drug-company oversight or business practices, while supporters would likely argue it prevents interference with a federal discount program intended to help safety-net providers. Another possible issue is the bill’s enforcement structure, which places authority with the pharmacy board and attorney general but denies a private right of action, potentially drawing differing views from providers, manufacturers, and regulators.